Finding 504393 (2023-001)

Significant Deficiency Repeat Finding
Requirement
P
Questioned Costs
-
Year
2023
Accepted
2024-11-01
Audit: 326962
Organization: Rtog Foundation, Inc. (PA)

AI Summary

  • Core Issue: The Foundation lacks proper segregation of duties for approving payments to subcontractors, as the project manager is employed by the subcontractor.
  • Impacted Requirements: This situation violates internal control standards, increasing the risk of undetected errors or fraud in financial transactions.
  • Recommended Follow-Up: Assign an independent person to review subcontractor payment requests before they are approved by the Board.

Finding Text

Finding 2023-001: Segregation of Duties Criteria: A strong internal control structure requires that duties be segregated so that one person does not have the ability to control all aspects of accounting functions. Adequate segregation of duties should exist among those who review and approve payments and those who prepare and submit the requests for payment. Statement of Condition: RTOG Foundation, Inc. (Foundation) does not have adequate segregation of duties present for the approval of payments to subcontractors, which are reflected as federal subcontracts expense on the financial statements. During 2023, the project manager, who was responsible for reviewing and approving the subcontractor’s invoices in preparation for payment authorization by members of the Foundation’s Board, was employed by the subcontractor. Cause: The Foundation does not have employees and is operated by a volunteer Board of Directors. The project manager had the knowledge and availability to review the invoice submissions and related supporting documents on behalf of the Foundation. Effect: A lack of segregation of duties increases the risk that errors or fraud relating to subcontractor invoices could occur and not be detected or that unallowable costs could be incurred. Recommendation: We recommend that the Foundation designate a person independent of the subcontractor to perform the initial review of the subcontractor’s requests for payment in advance of the payment authorization by the Foundation’s Board. Views of Responsible Officials: Management agrees with finding; see separate corrective action plan.

Corrective Action Plan

Finding 2023-001 – Segregation of Duties Statement of Condition: The Foundation does not have adequate segregation of duties present for the approval of payments to subcontractors, which is reflected as federal subcontracts expense on the financial statements. The project manager, who was responsible for reviewing and approving the subcontractor’s invoices in preparation for payment authorization by members of the Foundation’s Board, was employed by the subcontractor. Management Response: In August of 2022, the RTOG Foundation Inc. executed a Financial Management Services Agreement with the NSABP Foundation Inc. to provide oversight and management of financial statement preparation. The independent resources provided under this contract include day to day financial support from a Director of Finance with a supporting staff of accountants, financial analysts, and top-level oversight by a Senior Director of Finance with extensive experience in the financial management of clinical trials. The prior project manager referenced above has relinquished all financial accounting responsibilities and appropriate segregation of duties has been achieved, including, but not limited to, internal controls surrounding the payment of invoices. Routine financial analysis, account reconciliations, treasury functions, audit support and budgeting are also included under this services agreement. Monthly financial results are reviewed with the Board of Directors at regularly scheduled meetings.

Categories

Allowable Costs / Cost Principles Internal Control / Segregation of Duties

Other Findings in this Audit

  • 504394 2023-002
    Material Weakness Repeat
  • 504395 2023-001
    Significant Deficiency Repeat
  • 504396 2023-002
    Material Weakness Repeat
  • 504397 2023-001
    Significant Deficiency Repeat
  • 504398 2023-002
    Material Weakness Repeat
  • 504399 2023-001
    Significant Deficiency Repeat
  • 504400 2023-002
    Material Weakness Repeat
  • 504401 2023-001
    Significant Deficiency Repeat
  • 504402 2023-002
    Material Weakness Repeat
  • 504403 2023-001
    Significant Deficiency Repeat
  • 504404 2023-002
    Material Weakness Repeat
  • 1080835 2023-001
    Significant Deficiency Repeat
  • 1080836 2023-002
    Material Weakness Repeat
  • 1080837 2023-001
    Significant Deficiency Repeat
  • 1080838 2023-002
    Material Weakness Repeat
  • 1080839 2023-001
    Significant Deficiency Repeat
  • 1080840 2023-002
    Material Weakness Repeat
  • 1080841 2023-001
    Significant Deficiency Repeat
  • 1080842 2023-002
    Material Weakness Repeat
  • 1080843 2023-001
    Significant Deficiency Repeat
  • 1080844 2023-002
    Material Weakness Repeat
  • 1080845 2023-001
    Significant Deficiency Repeat
  • 1080846 2023-002
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.395 Cancer Treatment Research $2.20M
93.399 Cancer Control $664,945
93.394 Cancer Detection and Diagnosis Research $12,018